Login

I cannot remember my username

Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Flash Sell: Sail Away From Our December Trade With a 210% Profit!

By Ray BlancoPosted July 17, 2015

This company has been rising in part due to good news from its research and development efforts. Today, I want you to take a big profit from this company that just turned into a triple!

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

LoginGet Access

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits,
Ray Blanco's Pot Stock Mastermind, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2018, his closed positions in Technology...

View More By Ray Blanco

Related Posts

Back From Vancouver With Portfolio Updates

By Ray BlancoPosted August 3, 2012

I had a wonderful time meeting many of you in Vancouver last week. I enjoyed spending time with attendees from past years, as well as making some new friends. Now that I'm back, I'd like to update you on some of our biotech recommendations. Following on U.S. regulatory approval earlier this year, Vertex (NASDAQ: VRTX) just received approval in Europe for Kalydeco. By correcting for defective proteins regulating the transport of ions across cellular membranes, Kalydeco is the first-ever available cystic fibrosis therapy attacking the roots of the disease.

FLASH SELL: Take 250% Gains on This Cancer Innovator Now

By Ray BlancoPosted March 21, 2014

Our August 2012 pick reported some fantastic news last night. The European Committee for Medicinal Products for Human Use (CHMP) recommended approval for their groundbreaking drug. The European Medicines Agency (EMA) will issue a final decision soon -- in about three months. There has been a good deal of negative speculation recently in the financial press, so the positive CHMP decision comes as a surprise to many. Our recommendation’s shares, which were already up some 90% in our portfolio, skyrocketed over 100% in morning trading. Right now, we are sitting on a 250% gain from our original recommendation.

It’s Time to Sell This Superbug Slayer

By Ray BlancoPosted December 11, 2014

Antibiotics were a long-ignored corner of the pharmaceutical world, but they've become red-hot again. A year ago, I told you to buy the biggest of the few antibiotics pure plays on the market. That's paid off. On Monday, Merck announced it would buy the company at $102 per share. That's a 65% gain from when we recommended buying the antibiotics specialist.

Riding The Next Green Wave

By Ray BlancoPosted August 16, 2019
New Alert

One of the premier cannabis company has seen shares sell-off recently, which gives us a great buying opportunity! And today, Ray explains just how this pot stock is positioning itself to dominate the global marijuana market…